Key facts
- This page summarizes Jason A. Okazaki's Form 4 filing for ASSEMBLY BIOSCIENCES, INC. (ASMB).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Apr 2025, 16:05.
Jason A. Okazaki - 29 Mar 2025 Form 4 Insider Report for ASSEMBLY BIOSCIENCES, INC. (ASMB)
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- ASMB
- Reported as of
- 29 Mar 2025
- Net transaction value
- -$3,496
- SEC form
- 4
- Accepted by SEC
- 01 Apr 2025, 16:05:07 UTC
- Prior SEC filing
- 04 Oct 2024
- Next SEC filing
- 31 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ John O. Gunderson, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason A. Okazaki filed Form 4 for ASSEMBLY BIOSCIENCES, INC. (ASMB) on 01 Apr 2025.
Change
- Previous filing in this sequence was filed on 04 Oct 2024.
- Current net transaction value: -$3,496.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ASMB
transaction
Common Stock
Sale
- Transaction value
- $3,496
- Shares
- -355
- Change %
- -2.3%
- Price
- $9.85
- Shares after
- 14,757
- Date
- 31 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ASMB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +71,100
- Change %
- Price
- $0.000000
- Shares after
- 71,100
- Date
- 29 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 71,100
- Exercise price
- $10.62
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.56 to $10.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.
Footnote F3
Includes 208 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on November 14 14, 2024.
Footnote F4
Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2026; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2029.